ClinConnect ClinConnect Logo
Search / Trial NCT06879249

The Effect of CUGP Fluid Management in Patients With Sepsis or Septic Shock

Launched by SHUSHENG LI · Mar 11, 2025

Trial Information

Current as of April 22, 2025

Recruiting

Keywords

Sepsis, Septic Shock, Fluid Management, Critical Ultrasonography, Volume Responsiveness

ClinConnect Summary

This clinical trial is studying a special method called critical ultrasonography guided precise fluid management (CUGP) to see if it can help patients with sepsis or septic shock. Sepsis is a serious condition that happens when the body has an extreme response to an infection, which can lead to organ failure. The goal of the study is to find out if using CUGP can improve how fluids are managed in these patients, potentially leading to better health outcomes.

To participate in this trial, individuals need to be at least 18 years old and expected to stay in the intensive care unit (ICU) for at least 24 hours. They must also have a diagnosis of sepsis based on specific medical criteria. However, certain individuals are not eligible, including those who are pregnant or have certain serious health conditions like severe heart or lung problems. Participants can expect close monitoring and support while receiving the CUGP method, and their experience will help researchers understand its effectiveness in treating sepsis.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years old;
  • 2. Estimated length of ICU stay ≥ 24 hours;
  • * 3. Diagnosis according to the Sepsis 3.0 criteria, which included:
  • a. suspected or confirmed infections supported by clinical evidence and/or positive microbiological findings;
  • b. the sepsis related organ failure assessment (SOFA) score ≥ 2.
  • Exclusion Criteria:
  • 1. Patients were pregnant woman;
  • 2. Patients had acute coronary syndrome;
  • 3. Patients had acute pulmonary edema;
  • 4. Patients had status asthmatics;
  • 5. Patients had malignant arrhythmia;
  • 6. Patients had active gastrointestinal bleeding;
  • 7. Patients had epileptic seizure;
  • 8. Patients had drug poisoning;
  • 9. Patients had severe burns;
  • 10. Patients had contraindications of blood transfusion;
  • 11. Patients had intra-abdominal hypertension (intra-abdominal pressure increases continuously ≥ 12mmHg);
  • 12. Patients had acute pulmonary embolism;
  • 13. Patients had contraindications of leg raising;
  • 14. Patients had cardiac structural or functional abnormalities (left ventricular outflow tract obstruction, moderate-to-severe mitral regurgitation, aortic regurgitation), it would seriously affect the velocity time integral of left ventricular outflow tract;
  • 15. Patients or their legal representatives refused active treatment;
  • 16. Patients or their legal representatives refused to participate in this study;
  • 17. Patients were participating in other interventional clinical trials.

Trial Officials

Shusheng Li, PhD

Principal Investigator

Tongji Hospital

About Shusheng Li

Dr. Shusheng Li is a distinguished clinical trial sponsor known for his commitment to advancing medical research and innovation. With a robust background in clinical pharmacology and a focus on developing novel therapeutic strategies, Dr. Li leads a team dedicated to conducting high-quality clinical trials that adhere to regulatory standards and ethical guidelines. His expertise encompasses a wide range of therapeutic areas, ensuring that each study not only aims to improve patient outcomes but also contributes valuable data to the scientific community. Through strategic collaborations and a patient-centered approach, Dr. Li is at the forefront of transforming healthcare solutions.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported